Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma is a phase 3, randomised interventional study registered as NCT06858410 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 36 participants, started 2025-03 and due to reach its primary completion in 2030-03. Interventions recorded: lorlatinib; concurrent/sequential platinum-based chemoradiotherapy. Conditions listed: Neoadjuvant Non-Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS). Lung eligibility wording from the registry: "* Study Population: Patients with histologically or cytologically confirmed diagnosis of ALK-positive, lung adenocarcinoma who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the International Association for the Study of Lung Cancer \[IASLC\])". No results are recorded here; the registry entry is the source.